Abstract: In controlled group sequential trials, we consider the ratio of normal means as the effect measure of interest and derive group sequential nested confidence intervals on this parameter. In an interim analysis, the sample sizes of the following stages can be determined in a completely adaptive way using the unblinded data from all previously performed stages. Despite the data-dependent adaptation, the nested confidence intervals always keep the predefined confidence coefficient.
Introduction
In clinical trials, the difference or the ratio of normal means are the common effect measures for showing at least noninferiority of a new treatment compared to a standard (active) treatment. Provided the standard treatment is well known and stable in different populations, the suitable effect measure is the difference of means. Otherwise, the scale invariant ratio of means is the preferred effect measure.
In analyzing the trials, the confidence interval approach is of particular attractiveness.
Group sequential confidence intervals for the difference of means are known as repeated confidence intervals, see Jennison and Turnbull (2000) and references cited therein, Hartung and Knapp (2006) .
A well-known confidence interval for the ratio of normal means was derived by Fieller (1940) . Fieller parameterized a F -statistic, where the ratio of the means, say λ, is the parameter of interest. The boundaries of the confidence interval are found by equating the F -statistic to quantiles of an appropriate F -distribution and solving for the unknown parameter. The boundaries are given by solving a quadratic equation, see also Finney (1964) . In spite of its practical importance, the ratio of means does not seem to be considered in group sequential trials until now, neither for testing noninferiority nor for deriving confidence intervals.
In this paper, we will extend the proceeding of Fieller (1940) to group sequential trials that are designed for a fixed number, say K, of independent stages, where the ratio of normal means is the parameter of interest. We consider pivotal t-statistics in each stage involving the unknown parameter λ and combine the pivotal statistics using the inverse normal method from meta-analysis, see for instance Hartung, Knapp, and Sinha (2008) . As with Fieller's confidence interval, the multi-stage confidence intervals are defined implicitly and, for obtaining the boundaries, nonlinear equations have to be solved. However, the solutions are always unique.
In each stage k, 1 ≤ k ≤ K, a confidence interval on λ will be computed using the data of all previous stages. The consecutive intersection of these individual confidence intervals leads to a sequence of intervals that are nested. This property is of particular interest in the confidence interval approach to the analysis of noninferiority trials, see Bauer and Kieser (1996) and, for instance, the clinical trial guideline EMEA (2000) . Practically this means that the position of the confidence interval determines the kind of result of the study, independently of the question, whether the study has been originally planned as a noninferiority or as a superiority trial. The consequence of the proposed confidence interval intersection-approach is that, if we gain significance for noninferiority at an early stage of the trial, we will not take a risk to lose this significance in case we decide to continue the trial for an attempt of showing superiority.
In group sequential trials, interim analyses are based on the unblinded data. Since stochastically independent and uniformly distributed p-values will be combined for constructing the confidence intervals, the information from the interim analyses of the previous stages may be used for an adaptive sample size calculation of the following stage, see Brannath, Posch, and Bauer (2002), Hartung (2006) . We will provide concrete rules for updating sample sizes during the course of the group sequential trial.
The outline of the present paper is as follows: In Section 2.1, one-sided group sequential confidence intervals for the ratio of normal means are derived. Moreover, we consider the change from showing noninferiority to showing superiority during the course of the group sequential trial. In Section 2.2, two-sided confidence intervals and a test on the homogeneity of the ratios of the mean treatment effects underlying the K independent stages are presented. A group sequential confidence interval on the variance parameter is given in Section 3. General adaptive sample size planning is considered in Section 4. In Section 5, a real data example is presented that uses an adaptive design of O'Brien and Fleming (1979) type. In the example, the switching from showing superiority to showing noninferiority is shown during the ongoing trial. Moreover, after the first interim analysis, the design was changed from a three-stage into a two-stage design and we will show how to make full use of the type I error rate despite the shortening of the originally planned trial, that is, we will not lose any power. Some final remarks are given in Section 6, where especially point estimation of the ratio λ is briefly addressed.
Group Sequential Confidence Intervals for the Ratio of Normal Means
Let X E and X C be stochastically independent normally distributed random variables with mean µ E ≥ 0 in an experimental group E, mean µ C > 0 in an active control group C, and common variance σ 2 > 0, succinctly, X E ∼ N (µ E , σ 2 ) and X C ∼ N (µ C , σ 2 ). The parameter of interest is the ratio of the means, say λ, that is,
Let ∆ 0 , with 0 ≤ ∆ 0 < 1, be a noninferiority margin, we are interested in hypothesis testing of
at a predefined level α, 0 < α < 1/2. The alternative hypothesis H 1,∆ stands for (∆-)noninferiority, 0 < ∆ ≤ ∆ 0 , and means superiority of the experimental group E with regard to the control group C for ∆ = 0.
We consider a comparative study which is carried out consecutively in a number of independent stages, say K. In the i-th stage, i = 1, . . . , K, let beX E i ≥ 0 andX C i > 0 the sample means of n E i ≥ 2 and n C i ≥ 2 responses in the respective treatment groups.
The variance parameter σ 2 is estimated in the i-th stage by the pooled sample variance
That is, for the true parameter λ, the pivotal statistic T i (λ) from (4) follows a central
Let F tν denote the cumulative distribution function of a t-variable with ν degrees of freedom, then it holds, for the 1 − p-value,
where U (0, 1) stands for the uniform distribution in the unit interval. Consequently, we obtain
with Φ −1 the inverse of the standard normal cumulative distribution function Φ.
The stages of the trial are assumed to be independent. Consequently, up to the j-th stage, we define the combining pivotal statistic
Let Y 1 , . . . , Y K , in general, be mutually independent N (0, 1)-distributed random variables. Then, for predefined level α, 0 < α < 1/2, positive critical values cv 1 , . . . , cv K may be defined which satisfy the following probability statement,
For fixed number of stages K and overall significance level α, we get an O'Brien and Jennison and Turnbull (2000, p. 192) .
Using critical values cv j defined by (8), we get the following probability statements for the combining pivotal statistic from (7),
Definition 1. The group sequential lower confidence sets on the ratio λ are defined as
By (9), we can directly state the following lemma:
Lemma 1. The lower confidence sets from Definition 1 are nested, that is,
and the confidence coefficient of CI k,L (λ) is at least 1 − α, and exactly 1 − α for k = K.
In order to show that these confidence sets are genuine intervals, we need a further lemma.
Lemma 2. The statistics Z j (λ), j = 1, . . . , K, from (7) are monotone decreasing in λ,
Proof. At first, we show that the pivotal t-statistics T i (λ), i = 1, . . . , K, are (strictly) monotone decreasing in λ for λ ≥ 0.
Suppressing the subscript i and putting
so that T (λ) is monotone decreasing for nonnegative λ. Since the functions F tν (·) and (7), are both (strictly) monotone increasing functions in their arguments, the function Φ −1 (F tν (T (λ))) is monotone decreasing in λ ≥ 0. Hence the combined statistic Z j (λ) from (7) is monotone decreasing in λ for λ ≥ 0.
Moreover, the combining pivotal statistic Z j (λ) is a bounded function with respect to λ ≥ 0, that is, see (7), for j = 1, . . . , K,
Let us define, in the j-th stage, the following individual lower confidence set for λ,
Then, by Lemma 2, the confidence set (14) is a connected lower bounded one-sided confidence interval on λ. This interval can also be described as
where
Note that the solution in (15) is unique and can be easily found iteratively using, for instance, the bisection method.
Since CI k,L from (10) is the intersection of the individual confidence intervals from
we can summarize the above findings as follows.
Theorem 1
The lower confidence interval on λ with a confidence coefficient of at least
Let us now apply these group sequential confidence intervals to the test problem (1) at level of at most α. At stage k, k = 1, . . . , K, using λ Lk from (17), we proceed as follows: 
Nested Two-Sided Confidence Intervals and Homogeneity of the Ratios of the Treatment Effects
Let us define in analogy to (10) the upper confidence sets for λ as
Again, the confidence sets are nested, that is,
and each confidence set has a confidence coefficient of at least 1 − α and exactly 1 − α for
Definition 2. The group sequential two-sided confidence set for λ in stage k, say CI k (λ), is defined as the intersection of the lower and the upper confidence sets from (10) and (18), respectively, that is,
Let I j,U (λ) = {λ ≥ 0 | −cv j ≤ Z j (λ)} denote the individual upper confidence set in the j-th stage. In analogy to (15), we get the following interval representation,
where λ U (j) uniquely solves:
So the upper confidence set CI k,U from (18) has the interval representation,
Summarizing the above considerations, we can formulate the following results.
Theorem 2. The two-sided confidence set CI k (λ) has the interval representation
where λ Lk is from (17) and λ U k is from (21). The confidence intervals are nested,
and each confidence interval has a confidence coefficient of at least 1 − 2α, 0 < α < 1/2. (15) and (20), the individual two-sided confidence interval in the k-th stage, then CI 1 = I 1 and
Depending on the choice of α, the two-sided confidence interval CI k from (22) may be empty, that is, it may occur that λ U k < λ Lk . For interpreting such an event, let us consider the extended model that each stage has an individual parameter, say then, by (6) and (8), the k-dimensional confidence region,
covers the parameter vector (λ 1 , . . . , λ k ) with the probability of at least 1 − 2α, 0 < α < 1/2. Note that CR k is not empty for all α ∈ (0, 1/2), as, for instance, the realized vector
When we assume that the parameters λ i are really identical, say λ i = λ, i = 1, . . . , k, then the k-dimensional parameter vector (λ, . . . , λ) k is covered by CR k , or, in other words, (λ, . . . , λ) k ∈ CR k with probability of at least 1 − 2α. But this is equivalent to λ ∈ CI k with probability of at least 1 − 2α. Thus, if CI k is empty for a common confidence level 1 − 2α, this will speak against the assumption of an identical ratio of mean treatment effects over the first k stages. This can formally be stated as a test on homogeneity of the ratios.
In testing
for some i 1 , i 2 ∈ {1, . . . , k}, k = 2, . . . , K, the homogeneity hypothesis H 0,hom (k) will be rejected at level of at most 2α, if the confidence interval CI k from (22) is empty. If H 0,hom (k * ) is rejected, then also H 0,hom (k) will be rejected for k * ≤ k ≤ K. An alternative to this homogeneity test does not seem to be known.
Finally, we would like to remark that, in the case K = 1, we can solve (15) and (20) explicitly, and we get Fieller's well-known confidence interval for the ratio of means, see Fieller (1940 ), Finney (1964 .
Group Sequential Confidence Intervals on the Variance Parameter
Let F χ 2 ν denote the cumulative distribution function of a χ 2 -variate with ν degrees of freedom. Using the pivotal χ 2 -statistics from (2), which are monotone decreasing in σ 2 > 0, we obtain, in analogy to (5),
leading to the combining pivotal statistics
which are monotone decreasing in σ 2 > 0.
Since the confidence level for the variance parameter is usually chosen lower than for the outcome measure, let cv 1 (κ), . . . , cv K (κ) denote critical values that yield the (one-
Let σ 2 L (j) and σ 2 U (j) be the unique solutions for σ 2 of the equations
Then, in analogy to (22), we build the confidence intervals for σ 2 as
. . , K − 1, and the confidence coefficients are at least 1 − 2κ, 0 < κ < 1/2. For small κ, an empty interval indicates that the assumptions of homogeneous variances over the stages may be violated.
Since descriptions of the standard deviation are preferable in documentation, we simply take the square root of the boundaries in V CI k and denote the resulting confidence interval on σ by V CI 1/2 k .
Adaptive Sample Size Planning for the Effect Measure Ratio of Means
Planning with equal sample sizes in both two groups and suppressing the subscript i, we
Let us first consider the test of the point hypotheses
Then, for given level α, 0 < α < 1, and power 1 − β, 0 < β < 1, the required sample size m is given as (one-sample formula)
Let s 2 0 > 0 be a prior value for σ 2 and ξ * = µ E 0 − (1 − ∆)µ C 0 > 0 be a parameter value in the alternative H 1,∆ , see (1), then the expected effect size ξ * /σ(X) in (28) is given as
Note that, for ease of presentation, we will use the normal sample size spending function from (28) in the following though we use t-statistics in fact. In practice, by correcting the sample size m with the variance of a t m−1 -variate, that is, by replacing m through m(m−1)/(m−3), m ≥ 4, the nearly exact sample size can be determined in a one-sample setting.
We introduce now two steering parameters for each stage j, say v j and w j , in order to cover a wide range of reasonable updating possibilities. We plan with equal sample sizes for both groups at each stage. After stage j, let be A j (∆) > 0 a value for the effect size ξ * /σ(X), where A j (∆) is defined below. Then, conditioned on A j (∆) > 0, a power (1) is approximately reached using t-statistics when the total sample size for both groups is chosen as
with Putting w j = 0, when the first sample based estimate in A j (∆) is below the second one, gives priority to the second term as a lower bound. The reverse choice of w j covers a situation considered in a two-stage trial by Liu and Chi (2001) , and Proschan, Liu, and
Hunsberger (2003), who also discussed the role of the effect size in updating sample sizes.
Recall now from (8) that it holds
In the group sequential trial, the hypothesis H 0,∆ will be rejected if Z j (1 − ∆) > cv j , see (7) and (9). Then, by (31), if we decide after stage j − 1 to omit the interim analyses j up to K − 1, we can assign the remaining weight √ K − j + 1 to the next final study part and build the final test statistic as
Note that it holds Z j,K (1 − ∆) ∼ √ K N (0, 1) under H 0,∆ , j = 1, . . . , K, and define
The test statistic Z j,K (1 − ∆) has to be compared with the K-th critical value cv K in testing H 0,∆ .
The p-value of testing H 0,∆ is given at stage i by use of T i (1 − ∆) as
Provided that a significant result has not been reached in the first j − 1 stages, that is,
. . , j − 1, and in the next study part we want to attain cv K by use of the final test statistiĉ
then the projected p-valuep j,K (∆) of the next study part should bê
To detect a deviation of the null-hypothesis H 0,∆ in direction of H 1 , ∆ at
the sample size for the next final study stage must be chosen using (30) as
If we do no want to finish the trial in this way and have in mind the originally planned K − (j − 1) further stages, we suggest choosing the sample size of stage j proportionally as
Recall that the sample sizes should be at least 2 in each stage and group.
For j = 1 andp 1,K = 1 − Φ cv K / √ K , we obtain the starting sample size of the group sequential trial as
with A 0 (∆) > 0 from (29) and 0 < β < 1/2. Since A 0 (1 − ∆) has the same structure as
is increasing in ∆, see Lemma 2, and n 1 is maximum for ∆ = 0, that is, the sample size is maximum for the superiority trial as it should be.
Starting with n 1 observations from (37) in the first stage and applying the proceeding presented above, we reach the full power 1 − β, conditioned on
latest in stage j = K, if the trial does not stop earlier because of shown significance.
Note that, see (5) and (33), we may formally define the p-values as suiting to the null-hypothesis that λ is the true parameter, see Cox and Hinkley (1974, p. 221 ). So we may apply the general result that, under the null-hypothesis, p-values preserve their distribution and independence (for continuous null-distributions) when sample sizes are adaptively chosen in a consecutive way, see Brannath, Posch, and Bauer (2002) . All the presented procedures are based on such p-values. Consequently, the statements of Section 2 and 3 remain valid when sample sizes are adaptively chosen as demonstrated in this section, see also Hartung (2006) . Since no early significant results were expected, the decision was made in favor of an adaptive three-stage design of O'Brien and Fleming (1979) type. Using the combining statistic (7), we obtain the constant critical values cv j = cons OBF (3, 0.025) = 3.471(= 2.004 √ 3) for j = 1, 2, 3 in (8), see Jennison and Turnbull (2000, p. 29), Hartung (2006, p. 533) . Planning with ∆ = 0 for showing superiority, we obtain the prior guess A 0 (0) = 0.2357, see (29), using the prior guesses for the means and the standard deviation from We started with n 1 = 128 patients because of the randomization scheme using blocks of size 8. In the first stage, we observedx E 1 = 2.67,x C 1 = 2.55, and s 1 = 0.81, see Table   1 , that led to Z 1 (1) = 0.8352, see (7). Equating Z 1 (λ) to the critical values 3.471 and to −3.471 and solving for λ yields the first confidence interval on the ratio λ = µ E /µ C as
It turned out that the prior guesses of the parameters were too optimistic with respect to the new drug. Therefore, we used only the observed values from the first stage in the further planning, especially as these values were based on a relatively large number of patients. Consequently, the weight w j in the sample size spending function (30) In the sample size spending function (30), we obtain now A 1 (0.10) = 0.3441 with w 1 = 1.
So, formula (35) yields M 2 (0.10) ≈ 56 patients for the total sample size of the two remaining planned stages leading to 32 patients in the second stage because of the block size of 8. Therefore, it was decided to save the effort with an additional interim analysis and to omit the originally planned second one. In the final study part, say stage 2/3, the sample size is n 2/3 = 56.
If we would use now the combining statistic (7), we could lose potential power of the test since we would not make full use of the predefined level α. However, based on the considerations in Section 4, we can use the combining statistic
in the final analysis, see (32). The final test statistic has then to be compared with the critical value cv 3 .
In the final stage 2/3, we observedx E 2 = 2.70,x C 2 = 2.56, and s 2 = 0.87, see In the final stage, we use, in analogy to the considerations above, the combining statis- 
Final Remarks
In this paper, we defined a two-sided confidence interval CI k on the ratio of normal means by intersecting the lower and upper one-sided confidence intervals CI k,L and CI k,U on this parameter with confidence coefficients of 1 − α, respectively. The confidence coefficient of the two-sided interval CI k is always at least 1 − 2α. If we use the critical values of the correspondent two-sided test at level 2α, we will get a two-sided confidence interval, say CI 0 k , that is slightly narrower than CI k for K ≥ 2, but has a confidence coefficient of at least 1 − 2α as well. Moreover, the final interval CI 0 K has a confidence coefficient of exactly 1 − 2α. However, using the lower boundary of CI 0 k for the test decision in the test problem (1) as given at the end of Section 2.1, the test level α cannot be guaranteed.
However, no severe differences between both two-sided intervals and test decisions are expected for practical applications, because, at least for α ≤ 0.05, the involved critical values are nearly identical, see Jennison and Turnbull (2000, p. 192) .
In Section 2.2, we presented the two-sided confidence intervals as CI k = CI k−1 ∩ I k , see Remark 1, where I k results from the boundaries in stage k alone and, thus, is always nonempty. Since I k has also a confidence coefficient of at least 1 − 2α, we could prefer I k to CI k , see, for instance, Jennison and Turnbull (2000, p. 192) in their corresponding settings. But, suppose that up to stage k − 1 the intersections CI , = 1, . . . , k − 1, are nonempty and CI k is empty for a common level α. That means, the nonempty interval I k lies completely outside the nonempty interval CI k−1 . Therefore, up to an error rate of 2α, see (24), we may consider that the ratios of the underlying mean treatment effects are no longer homogeneous in all the stages. So, with regard to statistical concerns, results from this stage k should not influence conclusions, or non-conclusions, from the previous stages.
Consequently, preferring I k to CI k does not provide a real advantage. Nevertheless, one may try to find an explanation for the revealed treatment behavior. Recall that under the model assumption of an identical ratio µ E /µ C in all the stages of the trial, the probability obtaining an empty interval CI k is bounded by 2α.
Moreover, let us consider the testing problem in a group sequential trial. In a superiority test, the null-hypothesis H 0,0 is rejected at level α in favor of H 1,0 if we observe Z k * (1) > cv k * in at least one stage k * ∈ {1, . . . , K} or, equivalently, the lower bound of I k * lies above 0. Suppose k * < K and the study is continued to obtain more data, for instance, for safety reasons in clinical trials. Then, in all further stages k > k * , we may observe Z k (1) ≤ cv k or that I k covers 0 without contradicting the already shown superiority.
This fact is able to induce misunderstandings in practical applications caused by a lack of knowledge of the theoretical background. The same problem may arise when, after a shown significant noninferiority, the trial is continued for an attempt to show superiority.
Such possible misunderstandings are avoided by using CI k instead of I k as proposed in the testing procedure, see Section 2.1. The automatically implied homogeneity test (24) would react if quite different results would have been observed in later stages.
Finally, let us briefly address point estimation of the parameters λ and σ 2 . The combined statistic Z j (λ) from (7) estimator, see Cox and Hinkley (1974, p. 273) .
For the variance parameter σ 2 , we use the combining statistic Z 
